RCE Charts, page-30

@Brc Absolutely, I could not agree with you anymore.

But the fact that R327 is a broad-spectrum antibiotic with what seems to be multiple application ability, hedges our bets on RECCE as a company. If any one of these uses becomes a commercial market drug then the market cap will be upwards of 1 billion. If R327 in fact proves to be a treatable application to fight sepsis… then my guess would be multiple billions.

I’m well aware that every biotech/ pharmaceutical company thinks they are onto a winner, but looking at the data from vivo studies I get a strong sense of encouragement and confidence that we are on the cusp of something big. Maybe its blind confidence. Maybe its because I’m heavily invested. Either way I’m in for the ride.